Abiopharma

Takeda的HyHubTM和HyHubTM Duo装置获FDA 510(k)批准，简化HYQVIA®给药流程

Takeda recibe la autorización 510(k) de la FDA para los dispositivos HyHubTM y HyHubTM Duo que simplifican la administración de HYQVIA®

Takeda recebe aprovação 510(k) da FDA para dispositivos HyHubTM e HyHubTM Duo, a fim de simplificar a administração de HYQVIA®

Takeda erhält FDA-Zulassung gemäß 510(k) für HyHubTM und HyHubTM Duo Duo zur Vereinfachung der Verabreichung von HYQVIA®

FDA approve FUROSEMIDE

FDA approve EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE

FDA approve AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL

FDA approve CASPOFUNGIN ACETATE

FDA approve TESTOSTERONE CYPIONATE

FDA approve CINACALCET HYDROCHLORIDE

FARO Technologies Inc (FARO) was removed from the list of traded instruments on NASDAQ exchange

General Announcement: Request for Lifting of Trading Halt - Sponsors Statement

Request for Lifting of Trading Halt: Request for Lifting of Trading Halt

General Announcement: Request for Lifting of Trading Halt - Sponsors Statement

Request for Lifting of Trading Halt: Request for Lifting of Trading Halt